EXAS
Exact Sciences Corp
Price performance
Mar 23, 2026About
Company activity
26 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 03/23 | EXAS | 8-K | Exact Sciences Merged with Abbott, Delisted from Nasdaq | — | — | — |
| 03/20 | EXAS | 8-K | Exact Sciences to Merge with Abbott Laboratories | — | — | — |
| 02/20 | EXAS | 8-K | Exact Sciences Shareholders Approve Merger with Abbott Laboratories | — | — | — |
| 02/13 | EXAS | 8-K | Exact Sciences Reports Strong Q4 and Full-Year 2025 Results and Announces Pending Merger with Abbott | — | — | — |
| 02/10 | EXAS | 8-K | Exact Sciences Announces Updated Financial Projections for Merger with Abbott Laboratories | — | — | — |
| 12/29/25 | EXAS | 8-K | Exact Sciences Announces Executive Compensation Adjustments Ahead of Merger with Abbott | — | — | — |
| 11/20/25 | EXAS | 8-K | Abbott to Acquire Exact Sciences in $21 Billion Deal | — | — | — |
| 11/03/25 | EXAS | 8-K | Exact Sciences Reports Strong Third Quarter 2025 Results | — | — | — |
| 08/06/25 | EXAS | 8-K | Exact Sciences Announces Second Quarter 2025 Results and Strategic Collaborations | — | — | — |
| 06/16/25 | EXAS | 8-K | Exact Sciences Approves Incentive Plans and Shareholder Votes at 2025 Annual Meeting | — | — | — |
| 05/01/25 | EXAS | 8-K | Exact Sciences Announces Strong Q1 2025 Results and Raises Guidance | — | — | — |
| 04/29/25 | EXAS | 8-K | Exact Sciences Appoints New Board Member Leslie Trigg | — | — | — |
| 02/19/25 | EXAS | 8-K | Exact Sciences Reports 2024 Revenue and Fourth Quarter Results | — | — | — |
| 01/13/25 | EXAS | 8-K | Exact Sciences Announces Preliminary Financial Results and New Credit Agreement | — | — | — |
| 01/06/25 | EXAS | 8-K | Exact Sciences Appoints Kim Popovits to Board of Directors | — | — | — |
| 11/05/24 | EXAS | 8-K | Exact Sciences Announces Third-Quarter 2024 Financial Results: Revenue Growth and Regulatory Approvals | — | — | — |
| 07/31/24 | EXAS | 8-K | Exact Sciences Reports Q2 2024 Results with Record Revenue and Adjusted EBITDA | — | — | — |
| 06/17/24 | EXAS | 8-K | Exact Sciences Announces 2024 Annual Meeting Shareholder Approvals | — | — | — |
| 06/03/24 | EXAS | 8-K | Exact Sciences Announces Leadership Changes and Reiterates Financial Guidance | — | — | — |
| 05/08/24 | EXAS | 8-K | Exact Sciences Announces First-Quarter 2024 Financial Results | — | — | — |
| 05/08/24 | EXAS | 8-K | Exact Sciences Files Prospectus Supplement for Share Resale | — | — | — |
| 04/25/24 | EXAS | 8-K | Dr. Freda Lewis-Hall to Retire from Exact Sciences Board | — | — | — |
| 04/17/24 | EXAS | 8-K | Exact Sciences Completes Debt Exchange Transaction | — | — | — |
| 04/15/24 | EXAS | 8-K | Exact Sciences Appoints Aaron Bloomer as New CFO | — | — | — |
| 02/21/24 | EXAS | 8-K | Exact Sciences Announces Record Revenue and Positive Free Cash Flow for Q4 2023 | — | — | — |
| 01/08/24 | EXAS | 8-K | Exact Sciences Announces Preliminary Q4 2023 Results and CFO Succession Plan | — | — | — |
EXAS filing record
Exact Sciences Corp (EXAS): 26 8-K filings summarized, the most recent on Mar 23, 2026.
What the 8-K filings said
- Mar 23, 2026 · high impact
Exact Sciences Corporation has merged with Abbott Laboratories, resulting in Exact Sciences becoming a wholly-owned subsidiary of Abbott. The merger, which closed on March 23, 2026, involved the conversion of Exact Sciences' common stock into cash and the cancellation of various stock-related awards. Additionally…
Exact Sciences Merged with Abbott, Delisted from Nasdaq - Mar 20, 2026 · high impact
Exact Sciences Corporation has received all regulatory approvals and clearances required to consummate its previously reported merger with Abbott Laboratories. The merger, which was approved by Exact Sciences' stockholders on February 20, 2026, is anticipated to close on March 23, 2026, subject to the satisfaction or…
Exact Sciences to Merge with Abbott Laboratories - Feb 20, 2026 · high impact
On February 20, 2026, Exact Sciences Corporation held a special meeting of stockholders where the majority approved the Merger Agreement with Abbott Laboratories. However, the Compensation Proposal related to the merger was rejected by a significant margin. The Adjournment Proposal to solicit additional proxies was…
Exact Sciences Shareholders Approve Merger with Abbott Laboratories - Feb 13, 2026 · high impact
Exact Sciences Corporation announced its financial results for Q4 and full-year 2025, reporting a 23% increase in total revenue to $878 million for Q4 and $3.25 billion for the full year. The company also reported improvements in operating cash flow and free cash flow. Exact Sciences also announced a pending merger…
Exact Sciences Reports Strong Q4 and Full-Year 2025 Results and Announces Pending Merger with Abbott - Feb 10, 2026 · high impact
Exact Sciences Corporation has announced updated financial projections for its pending merger with Abbott Laboratories. The company has amended its Definitive Proxy Statement to include additional financial analysis by Centerview Partners LLC. The analysis includes a discounted cash flow analysis, selected public…
Exact Sciences Announces Updated Financial Projections for Merger with Abbott Laboratories
SEC filings in the last five years
- 49 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K